Protagonist Says Cash And Equivalents Of $595.4M As Of June 30, 2024, Anticipated To Provide Cash Runway Through End Of 2027
Portfolio Pulse from Benzinga Newsdesk
Protagonist Therapeutics (PTGX) reported having $595.4 million in cash and equivalents as of June 30, 2024, which is expected to provide a cash runway through the end of 2027.
August 06, 2024 | 11:53 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Protagonist Therapeutics (PTGX) reported $595.4 million in cash and equivalents as of June 30, 2024, providing a cash runway through the end of 2027.
The substantial cash reserves and extended runway reduce financial risk and provide stability, which is likely to positively impact investor sentiment and the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100